Serum homocysteine level and severity of coronavirus disease-2019 (COVID-19)

1 HU Y., SUN J., DAI Z., DENG H., LI X., HUANG Q., et al. Prevalence and severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol. 2020;127:104371. Search in Google Scholar

2 RUSLIE RH., DARMADI D., SIREGAR GA. Susceptibility of coronavirus disease-19 in pediatric population. Open Access Maced J Med Sci. 2020;8: 363–5. Search in Google Scholar

3 RAHMAN S., MONTERO MTV., ROWE K., KIRTON R., KUNIK JR F. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021;14(5):601–21. Search in Google Scholar

4 RUSLIE RH., DARMADI D., SIREGAR GA. Pediatric immunization practice during coronavirus disease-2019 pandemic. Open Access Maced J Med Sci. 2020;8: 258–60. Search in Google Scholar

5 TONG-MINH K., VAN DER DOES Y., ENGELEN S., DE JONG E., RAMAKERS C., GOMMERS D., et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect Dis. 2022;22(1):165. Search in Google Scholar

6 World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: covid19.who.int. Accessed 6 October 2022. Search in Google Scholar

7 ZHANG N., XIE T., NING W., HE R., ZHU B., MAO Y. The severity of COVID-19 and its determinants: a systematic review and meta-analysis in China. Sustainability. 2021;13(9):5305. Search in Google Scholar

8 GHAHRAMANI S., TABRIZI R., LANKARANI KB., KASHANI SMA., REZAEI S., ZEIDI N., et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):30. Search in Google Scholar

9 LAMERSs MM., HAAGMANS BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270–84. Search in Google Scholar

10 RUSLIE RH., DARMADI D. Coronavirus disease-2019 and mental health. Open Access Maced J Med Sci. 2020;8: 268–71. Search in Google Scholar

11 PONTI G., MACCAFERRI M., RUINI C., TOMASI A., OZBEN T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–99. Search in Google Scholar

12 ZENG F., HUANG Y., GUO Y., YIN M., CHEN X., XIAO L., et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. 2020;96:467–74. Search in Google Scholar

13 SOLE FD., FARCOMENI S., LOFFREDO L., CARNEVALE R., MENICHELLI D., VICARIO T., et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13378. Search in Google Scholar

14 AHMEIDI AA., MUSA A., AHMED HS., ELAHMAR AA., GOOTA RB., AHMED IA., et al. Inflammatory markers as predictors of mortality in COVID-19 infection. Afr J Lab Med. 2020;9(1):a1298. Search in Google Scholar

15 CARPENE G., NEGRINI D., HENRY BM., MONTAGNANA M., LIPPI G. Homocysteine in coronavirus disease (COVID-19): a systematic literature review. Diagnosis (Berl). 2022;9(3):306–10. Search in Google Scholar

16 HUANG I., PRANATA R., LIM MA., OEHADIAN A., ALISJAHBANA B. C-reactive protein, procalcitonin, D-dimer, and feritin in severe coronavirus disease-2019: a meta analysis. Ther Adv Respir Dis. 2020;14:1753466620937175. Search in Google Scholar

17 KHEDAR RS., GUPTA R., SHARMA KK., MITTAL K., AMBALIYA HC., GUPTA JB., et al. Biomarkers and outcomes in hospitalized covid-19 patients: a prospective registry. medRxiv. 2022;20:22277718. Search in Google Scholar

18 KESKIN A., USTUN GU., ACI R., DURAN U. Homocysteine as a marker for predicting disease severity in patients with COVID-19. Biomark Med. 2022;16(7):559–68. Search in Google Scholar

19 PONTI G., PASTORINO L., MANFREDINI M., OZBEN T., OLIVIA G., KALECI S., et al. COVID-19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence. J Clin Lab Anal. 2021;35(7):e23798. Search in Google Scholar

20 DARMADI D., PAKPAHAN C., RUSLIE RH., REZANO A. Inflammatory laboratory findings associated with severe illness among hospitalized individuals with COVID-19 in Medan, Indonesia: a cross-sectional study. F1000Res. 2021; 10: 1246. Search in Google Scholar

21 HEIDARI-BENI F., VAHEDIAN-AZIMI A., SHOJAEI S., RAHIMI-BASHAR F., SHARIARY A., JOHNSTON TP., et al. The level of procalcitonin in severe COVID-19 patients: a systematic review and meta-analysis. Adv Exp Med Biol. 2021;1321:277–86. Search in Google Scholar

22 HEER RS., MANDAL AKJ., SZAWARSKI P., MISSOURIS CG. Procalcitonin is a biomarker for disease severity rather than bacterial co-infection in COVID-19. Eur J Emerg Med. 2022;29(4):315. Search in Google Scholar